Literature DB >> 6939330

Corneal toxicity with systemic cytarabine.

G Hopen, B J Mondino, B L Johnson, P A Chervenick.   

Abstract

Three patients with leukemia developed corneal toxicity while receiving high doses (3 g/m2) of systemic cytarabine. Symptoms began five to seven days after initiation of treatment with high doses of systemic cytarabine and consisted of ocular pain, tearing, foreign-body sensation, photophobia, and blurred vision. All three patients developed bilateral conjunctival hyperemia and fine corneal epithelial opacities and refractile microcysts that were more numerous in the central than in the peripheral cornea. The symptoms disappeared without treatment in approximately one week. The corneal changes we observed with high doses of systemic cytarabine resembled descriptions of corneal toxicity from topical cytarabine and were probably secondary to inhibition of DNA synthesis in the corneal epithelium.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6939330     DOI: 10.1016/0002-9394(81)90240-3

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  12 in total

1.  Ocular surface toxicity associated with topical interferon alpha-2b.

Authors:  Anthony J Aldave; Anne Nguyen
Journal:  Br J Ophthalmol       Date:  2007-08       Impact factor: 4.638

Review 2.  Ocular toxicity from systemically administered xenobiotics.

Authors:  Mitan R Gokulgandhi; Aswani Dutt Vadlapudi; Ashim K Mitra
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-07-18       Impact factor: 4.481

3.  Posterior segment toxicity after gemcitabine and docetaxel chemotherapy.

Authors:  Ali Kord Valeshabad; William F Mieler; Vikram Setlur; Merina Thomas; Mahnaz Shahidi
Journal:  Optom Vis Sci       Date:  2015-05       Impact factor: 1.973

Review 4.  High-dose cytosine arabinoside: pharmacological and clinical aspects.

Authors:  W G Peters; L P Colly; R Willemze
Journal:  Blut       Date:  1988-01

5.  Prophylactic treatment for cytosine arabinoside-induced keratoconjunctivitis.

Authors:  A K Patel; W Sheehan; A Jenkins; C Lane; J Kell
Journal:  Int Ophthalmol       Date:  2011-03-18       Impact factor: 2.031

Review 6.  The toxicity of cytarabine.

Authors:  J Stentoft
Journal:  Drug Saf       Date:  1990 Jan-Feb       Impact factor: 5.606

7.  Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma.

Authors:  Hui K Gan; David A Reardon; Andrew B Lassman; Ryan Merrell; Martin van den Bent; Nicholas Butowski; Zarnie Lwin; Helen Wheeler; Lisa Fichtel; Andrew M Scott; Erica J Gomez; JuDee Fischer; Helen Mandich; Hao Xiong; Ho-Jin Lee; Wijith P Munasinghe; Lisa A Roberts-Rapp; Peter J Ansell; Kyle D Holen; Priya Kumthekar
Journal:  Neuro Oncol       Date:  2018-05-18       Impact factor: 12.300

Review 8.  Ocular Adverse Events Associated with Antibody-Drug Conjugates in Human Clinical Trials.

Authors:  Joshua Seth Eaton; Paul E Miller; Mark J Mannis; Christopher J Murphy
Journal:  J Ocul Pharmacol Ther       Date:  2015-11-05       Impact factor: 2.671

9.  N-acetylcysteine supplementation reduces oxidative stress for cytosine arabinoside in rat model.

Authors:  Yasemin Isik Balci; Semra Acer; Ramazan Yagci; Vural Kucukatay; Hakan Sarbay; Kerem Bozkurt; Aziz Polat
Journal:  Int Ophthalmol       Date:  2016-05-23       Impact factor: 2.031

10.  Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.

Authors:  David A Reardon; Andrew B Lassman; Martin van den Bent; Priya Kumthekar; Ryan Merrell; Andrew M Scott; Lisa Fichtel; Erik P Sulman; Erica Gomez; JuDee Fischer; Ho-Jin Lee; Wijith Munasinghe; Hao Xiong; Helen Mandich; Lisa Roberts-Rapp; Peter Ansell; Kyle D Holen; Hui K Gan
Journal:  Neuro Oncol       Date:  2017-07-01       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.